This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.

The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the V.sub.H, V.sub.L, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

A multi-analyte sensor includes a body having a proximal end and a distal end. A plurality of strips is connected to one end of the body and a plurality of electrical conductors run through the body and into the plurality of strips. Exposed portions of first and second electrical conductors running through first and second strips are coated with analyte-responsive materials, such as a first molecular imprinted polymer (MIP) and a second MIP, respectively. The first MIP has binding sites for a first target analyte and the second MIP has binding sites for a second target analyte. The multi-analyte sensor may be part of a sensing device that also includes a controller and a data store.

Improved methods and systems for diagnosing and for treating Cushing's syndrome and Cushing's Disease are provided herein, including methods and systems for concurrently treating Cushing's syndrome and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome in a patient with an established diagnosis of ACTH-dependent Cushing's syndrome. Treatment methods can use glucocorticoid receptor antagonists (GRAs), which differentially affect the ratio of cortisol to ACTH levels in patients having Cushing's Disease versus patients having Ectopic Cushing's Syndrome. Methods for concurrently treating and differentially diagnosing Cushing's Disease from Ectopic Cushing's Syndrome include obtaining baseline cortisol and ACTH levels of a patient, treating the patient with a GRA according to a protocol that would typically substantially elevate cortisol levels, obtaining post-treatment cortisol and ACTH levels of the patient, determining a differential relationship between baseline cortisol and ACTH levels and post-treatment cortisol and ACTH levels and providing a positive diagnosis based on the differential relationship.

This invention relates the use of cortisol blockers (glucocorticoid receptor [GR] antagonists) for the treating or preventing treatment resistant prostate cancer, treating or preventing neoplasia, and treating or preventing infection related to acute or chronic injury or disease.

Diagnosing an oxidative stress (OS) in companion animals comprises screening a bodily fluid sample to detect the presence of an OS biomarker, selectively isoprostane and antioxidants, HODE, microRNAs, TAC, GSH, MDA, and TNF-alpha. The sample can be saliva.

The present invention relates to a method for preparing anti-mammalian AMH antibodies comprising the steps of: (i) immunizing an animal with an AMH polypeptide or a polynucleotide encoding this AMH polypeptide, said AMH polypeptide comprising at least the 99 amino acids of sequence SEQ ID No. 1 or of a sequence having at least 75% identity with the sequence SEQ ID No. 1, and at most the 560 amino acids of sequence SEQ ID No. 2 or of a sequence having at least 75% identity with the sequence SEQ ID No. 2, (ii) preparing hybridomas from cells of a lymphoid organ of the animal having received the immunogen, (iii) selecting hybridomas secreting antibodies recognizing an AMH polypeptide comprising at least the 99 amino acids of sequence SEQ ID No. 1 or of a sequence having at least 75% identity with the sequence SEQ ID No. 1, and at most the 255 amino acids of sequence SEQ ID No. 8 or of a sequence having at least 75% identity with the sequence SEQ ID No. 8, but recognizing neither (a) an AMH polypeptide comprising at least the 131 amino acids of sequence SEQ ID No. 13 or of a sequence having at least 75% identity with the sequence SEQ ID No. 13 and at most the 156 amino acids of sequence SEQ ID No. 11 or of a sequence having at least 75% identity with the sequence SEQ ID No. 11, nor (b) any linear epitope located in the sequence SEQ ID No. 1 or a sequence having at least 75% identity with the sequence SEQ ID No. 1, and (iv) producing the antibodies. The invention also relates to the antibodies and antibody fragments and the use of same for assaying AMH, in particular in fertility.

The disclosure provides methods for enriching for pancreatic endocrine progenitor cells, such as human pancreatic endocrine progenitor cells, including alpha cell progenitors, beta cell progenitors, delta cell progenitors, PP cell progenitors and epsilon cell progenitors. The disclosure provides mammalian, such as human, Fev.sup.+ pancreatic endocrine progenitor cells, including Fev.sup.+ alpha cell progenitors, Fev.sup.+ beta cell progenitors, Fev.sup.+ delta cell progenitors, Fev.sup.+ PP cell progenitors, and Fev.sup.+ epsilon cell progenitors. The disclosure further provides methods for producing or inducing such cells, including in vitro differentiation methods, and the cells so produced.

The present invention relates to a method for providing a verified analyte measurement of a sample with a chromatography mass spectrometer device, said method comprising the following steps: a) admixing an interferent monitoring compound and, optionally an internal standard, to the sample; b) determining a chromatogram of the sample by acquiring a plurality of data points for signal intensities over time for said interferent monitoring compound, said analyte, and optionally said internal standard; and c) comparing a property of an interferent monitoring compound peak to a property of an internal standard peak and/or to a property of an analyte peak; and to methods and systems related thereto.

Provided herein are methods for detecting neutralizing antibodies to leptins, including metreleptin, as well as identifying subjects having such neutralizing antibodies.